RxDoctor Payments Data

David Chin Yee, MD

Retina Specialist · Atlanta, GANPI 1740424563

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $597,618 of the $816,094 with a category attached, or 73.2%. 33 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 35.8% of the total.

$816,094in general payments, 2019–2025

Across 1,044 payments — averaging $781.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$292K
  • Astellas Pharma US Inc$154K
  • Apellis Pharmaceuticals, Inc.$138K
  • Genentech USA, Inc.$115K
  • Alimera Sciences, Inc.$41K
  • Novartis$36K
  • plus $39K from 27 others
$98,971in research payments, 2019–2025

Across 68 payments — averaging $1455.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$98K
  • Notal Vision, Inc.$1K

What the payments were for

  • Consulting fees$106,18813%
  • Speaking & faculty fees$597,61873%
  • Travel & lodging$83,00110%
  • Food & beverage$29,2484%
  • Gifts$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$3,424,822
Medicare patients
750
Services billed
51,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate143$7,706
Atropine Sulfate59$2,485
Brimonidine Tartrate27$1,919
Ketorolac Tromethamine50$1,460
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat62$776
Latanoprost33$703
Ciprofloxacin Hcl54$674
Dorzolamide Hcl21$375
MoxifloxacinMoxifloxacin Hcl11$335
Timolol Maleate31$327

Paid to pharmacies, not to this prescriber.

Other retina specialist in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →